Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis

Gavin Y Oudit, Andrew M Herzenberg, Zamaneh Kassiri, Denise Wong, Heather Reich, Rama Khokha, Michael A Crackower, Peter H Backx, Josef M Penninger, James W Scholey, Gavin Y Oudit, Andrew M Herzenberg, Zamaneh Kassiri, Denise Wong, Heather Reich, Rama Khokha, Michael A Crackower, Peter H Backx, Josef M Penninger, James W Scholey

Abstract

Angiotensin-converting enzyme-2 (ACE2), a membrane-bound carboxymonopeptidase highly expressed in the kidney, functions as a negative regulator of the renin-angiotensin system. Here we report early accumulation of fibrillar collagen in the glomerular mesangium of male ACE2 mutant (ACE2-/y) mice followed by development of glomerulosclerosis by 12 months of age whereas female ACE2 mutant (ACE2-/-) mice were relatively protected. Progressive kidney injury was associated with increased deposition of collagen I, collagen III and fibronectin in the glomeruli and increased urinary albumin excretion compared to age-matched control mice. These structural and functional changes in the glomeruli of male ACE2 mutant mice were prevented by treatment with the angiotensin II type-1 receptor antagonist irbesartan. Loss of ACE2 was associated with a marked increase in renal lipid peroxidation product formation and activation of mitogen-activated protein kinase and extracellular signal-regulated kinases 1 and 2 in glomeruli, events that are also prevented by angiotensin II type-1 receptor blockade. We conclude that deletion of the ACE2 gene leads to the development of angiotensin II-dependent glomerular injury in male mice. These findings have important implications for our understanding of ACE2, the renin-angiotensin system, and gender in renal injury, with ACE2 likely to be an important therapeutic target in kidney disease.

Figures

Figure 1
Figure 1
Normal architecture in young (3-month-old) ACE2 mutant mice with early ultrastructural changes. a: Whole mount of ACE2−/y mouse kidneys showing normal architecture (PAS, original magnification, ×16). b: ACE2−/y glomeruli are normal by light microscopy, comparable to ACE2+/y controls (PAS, original magnification, ×600). c: Electron microscopy shows early fibrillar collagen deposition (arrow) in the ACE2−/y mice but not in wild-type controls (original magnification, ×4800).
Figure 2
Figure 2
Glomerulosclerosis in old (1-year) ACE2 mutant mice. a: Whole mount of ACE2+/y, ACE2−/y, and ACE2−/− (female mutant mice) mouse kidneys show normal architecture (PAS, original magnification, ×16). b: ACE2−/y, but not ACE2+/yor ACE2−/−, glomeruli show glomerulosclerosis, segmental scarring, and hyalinosis (PAS, original magnification, ×600). c: Glomerulosclerosis scores of ACE2+/y, ACE2−/y, and ACE2−/− mice (*P < 0.01 vs. ACE2+/y and ACE2−/−).
Figure 3
Figure 3
a: Survey of glomerular pathological changes in 1-year-old male ACE2 mutant mice. The mesangium (m) shows expansion and foci of mesangial hypercellularity. There are numerous foci of glomerular capillary hyalinosis (ch) and segmental capillary microaneurysm (cma) formation. Focal segmental glomerulosclerosis (fgs) is evident in the form of segmental scarring with adhesions. Evidence of arteriolar hyalinosis (ah) is present only at glomerular hila, with sparing of extraglomerular arterioles (art) (PAS, original magnifications, ×600 and ×400 last panel). b: Electron microscopy shows mesangial cell transition to a smooth muscle cell phenotype (arrow) and increased fibrillar collagen deposition (arrowheads) in an expanded mesangium (m) (original magnification, ×4800). c: Urine protein electrophoresis showing that glomerulosclerosis was associated with the development of albuminuria (arrow) in 1-year ACE2−/y but not wild-type ACE2+/y mice. Lane 1 shows molecular weight (MW) markers.
Figure 4
Figure 4
Glomerular immunohistochemical profile of 1-year-old ACE2+/y and ACE2−/y mice. Far right panel shows computer image analysis scores of glomerular immunostaining. a: Collagen I. b: Collagen III. c: Fibronectin. d: α-Smooth muscle actin. As expected arterioles exhibit positive α-smooth muscle actin staining (arrows) in both ACE2+/yand ACE2−/y mice. Immunoperoxidase, original magnification, ×600 (a–d). *P < 0.05 versus ACE2+/y.
Figure 5
Figure 5
Kidneys of ACE−/−/ACE2−/y double mutant mice (n = 4). a: Whole mount of ACE−/−/ACE2−/y mouse kidneys show abnormal renal architecture. There is cortical and medullary thinning, cystic dilatation of the renal calyx, and an abnormal papilla, possibly due to hydronephrosis. b: Glomeruli of ACE−/−/ACE2−/y mouse are abnormal. Capillary loops are incomplete, small, and hyalinotic. The mesangium shows abnormal architecture characterized by a loose-appearing matrix. PAS stain, original magnifications, ×16 (a) and ×600 (b).
Figure 6
Figure 6
Treatment with the ARB irbesartan prevents development of glomerulosclerosis in ACE2 mutant mice. a: Whole mount of ACE2+/y mouse kidney and glomerulus. b: ACE2−/y mouse kidney, treated with placebo, showing normal gross architecture. The glomerulus shows segmental sclerosis, capillary hyalinosis, and capillary microaneurysm formation. c: ARB-treated ACE2−/y mice (ACE2−/y ARB) show normal gross architectural features and glomeruli, comparable to ACE2+/y mice. d: Glomerulosclerosis scores: *P < 0.05 vs. ACE2−/y ARB. PAS stain, original magnifications, ×16 (whole mounts), ×600 (glomeruli) (a–c). e: Urine protein electrophoresis of ACE2−/y ARB mice. There is no detectable albumin in the urine of the ARB-treated ACE2−/y mice (lanes 1 to 5). Lane 6 shows molecular weight (MW) markers.
Figure 7
Figure 7
Kidney levels of the lipid peroxidation products, hexanal (a), malondialdehyde (b), and hydroxynonenal (c) in male ACE2+/y, male ACE2−/y, ARB-treated male ACE2−/y, female ACE2+/+, and female ACE2−/− mice. *P < 0.05 versus male ACE2+/y, ARB-treated male ACE2−/y, female ACE2+/+, and female ACE2−/− mice.
Figure 8
Figure 8
Phospho-ERK1/2 immunohistochemistry of mouse glomeruli. a: Increased nuclear staining of phospho-ERK1/2 is observed in the male ACE2−/y mouse glomerulus, compared to male ACE2+/y, ARB-treated male ACE2−/y, and female ACE2−/− mouse glomeruli (magnification, ×600). b: Quantitative score of phospho-ERK1/2-positive nuclei per glomerular cross-section in the four groups of mice. *P < 0.01 versus ACE2+/y, ARB-treated ACE2−/y, and female ACE2−/− mice.
Figure 9
Figure 9
Renal expression of components of the RAS in ACE2+/y, ACE2−/y, and ARB-treated ACE2−/y mice by real-time RT-PCR for AT1 (a), AT2 (b), and ACE (c). d: Immunohistochemical study of AT1 receptor protein expression in the renal cortex of male ACE2+/y and male ACE2−/y mice. e: Quantitative scoring of AT1 receptor expression (P < 0.01 vs. ACE2+/y mice).

References

    1. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803–1817.
    1. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002;1:621–636.
    1. Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003;13:93–101.
    1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462.
    1. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P, The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–945.
    1. Investigators HOPES. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259.
    1. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.
    1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
    1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
    1. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25:291–294.
    1. Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci. 2004;61:2720–2727.
    1. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase. J Biol Chem. 2002;277:14838–14843.
    1. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, Diz DI. Vasopeptidase inhibition and Ang-(1–7) in the spontaneously hypertensive rat. Kidney Int. 2002;62:1349–1357.
    1. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258–8263.
    1. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454.
    1. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828.
    1. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41:392–397.
    1. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, Liu PP, Backx PH. L-type Ca(2+) channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187–1194.
    1. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res. 2005;97:380–390.
    1. Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzi P, Gordon K, Gown AM. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest. 1991;87:847–858.
    1. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM. Renal injury from angiotensin II-mediated hypertension. Hypertension. 1992;19:464–474.
    1. Gorin Y, Ricono JM, Wagner B, Kim NH, Bhandari B, Choudhury GG, Abboud HE. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J. 2004;381:231–239.
    1. Agarwal R, Campbell RC, Warnock DG. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol. 2004;24:101–114.
    1. Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA. 2004;101:13302–13305.
    1. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–1456.
    1. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M, Egido J. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl. 2003:S64–S70.
    1. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, Kaneko K, Yamashiro Y, Ogawa H, Nakao A. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int. 2004;66:597–604.
    1. Niimura F, Labosky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa T, Ichiki T, Naftilan AJ, Fogo A, Inagami T, Hogan BLM, Ichikawa I. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest. 1995;96:2947–2954.
    1. Davisson RL, Kim HS, Krege JH, Lager DJ, Smithies O, Sigmund CD. Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. J Clin Invest. 1997;99:1258–1264.
    1. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O’Brien DA, Smithies O. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature. 1995;375:146–148.
    1. Oliverio MI, Kim HS, Ito M, Le T, Audoly L, Best CF, Hiller S, Kluckman K, Maeda N, Smithies O, Coffman TM. Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci USA. 1998;95:15496–15501.
    1. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, Fogo A, Utsunomiya H, Inagami T, Ichikawa I. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest. 1998;101:755–760.
    1. Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O, Alhenc-Gelas F. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA. 2001;98:13330–13334.
    1. Esther CR, Jr, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest. 1996;74:953–965.
    1. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319–329.
    1. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, Koch A, Hamar P, Amann K, Ritz E. Beneficial effects of estrogens on indices of renal damage in uninephrectomized SHRsp rats. J Am Soc Nephrol. 2004;15:348–358.
    1. Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, Striker GE, Striker LJ. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol. 2003;162:1441–1448.
    1. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55:278–285.
    1. Reyes D, Lew SQ, Kimmel PL. Gender differences in hypertension and kidney disease. Med Clin North Am. 2005;89:613–630.
    1. Silbiger S, Lei J, Ziyadeh FN, Neugarten J. Estradiol reverses TGF-beta1-stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol. 1998;274:F1113–F1118.
    1. Krepinsky J, Ingram AJ, James L, Ly H, Thai K, Cattran DC, Miller JA, Scholey JW. 17β-Estradiol modulates mechanical strain-induced MAPK activation in mesangial cells. J Biol Chem. 2002;277:9387–9394.
    1. Mankhey RW, Bhatti F, Maric C. 17β-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol. 2005;288:F399–F405.
    1. Baumer AT, Wassmann S, Ahlbory K, Strehlow K, Muller C, Sauer H, Bohm M, Nickenig G. Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol. 2001;134:579–584.
    1. Itagaki T, Shimizu I, Cheng X, Yuan Y, Oshio A, Tamaki K, Fukuno H, Honda H, Okamura Y, Ito S. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress-induced activation of cultured rat hepatic stellate cells. Gut. 2005;54:1782–1789.
    1. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, Nahmias C, Ito M, Horiuchi M. Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension. 2002;39:41–45.
    1. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med. 2005;11:867–874.
    1. Haugen EN, Croatt AJ, Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int. 2000;58:144–152.
    1. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res. 2002;91:406–413.
    1. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431–2437.
    1. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998;31:181–188.
    1. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38:635–638.
    1. Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science. 2001;292:2083–2086.
    1. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension. 2004;43:1120–1125.
    1. Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. J Pathol. 2004;204:587–593.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する